<DOC>
	<DOCNO>NCT01454336</DOCNO>
	<brief_summary>Liver cirrhosis ( LC ) final destiny chronic liver disease . Liver transplantation effective therapy available patient . However , limited number donor , post surgical complication , immunological rejection , financial consideration ` essential problem . The immuomodulatory impact MSCs fibrosis confirm , several clinical study apply MSCs eliminate progression fibrosis . In research investigator study affect MSCs Pioglitazone process fibrosis .</brief_summary>
	<brief_title>Transplantation Autologous Mesenchymal Stem Cell Decompensate Cirrhotic Patients With Pioglitazone</brief_title>
	<detailed_description>BM Aspiration do twice ( 6 month interval ) iliac crest accord standard procedure general anesthesia collect ( 200ML ) plastic bag contain anti coagulant . After precipitation red blood cell , mononuclear cell collect centrifugation Ficoll-Paque density gradient . MNCs culture T150 flask . Cells expand several subcultures.MSCs inject ( 6 month interval ) via portal vein sonography monitoring.Each patient receive 30mg Pioglitazone daily 24 month . After cell therapy , patient follow every week 6 month , laboratory data analyze 6 month .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>1865 Years cirrhotic patient Approved cirrhosis elastografy , biopsy , sonography 1 Portal vein thrombosis 2Hepatic encephalopathy , score 3 &amp; 4 3ALT &amp; AST 3times normal 4Serum Cr 1/5mg/dL 5 ( AntiHIV + ) ( AntiHCV+ ) ( HBSAg+ ) 6Hepatocel carcinoma 7 Primary sclerosing cholangitis ( PSC ) 8 Esophageal varix grade 4 9Addiction 10Child Score B , C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>MSCs</keyword>
	<keyword>Pioglitazon</keyword>
	<keyword>fibrosis</keyword>
	<keyword>liver</keyword>
</DOC>